Wedbush Issues Positive Forecast for MRSN Earnings

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Investment analysts at Wedbush lifted their Q2 2025 earnings estimates for Mersana Therapeutics in a report released on Tuesday, May 6th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.23) for the quarter, up from their previous forecast of ($0.26). Wedbush currently has a “Outperform” rating and a $3.00 price objective on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Wedbush also issued estimates for Mersana Therapeutics’ Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.80) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.53) EPS and FY2028 earnings at ($0.52) EPS.

Separately, William Blair began coverage on shares of Mersana Therapeutics in a report on Thursday, February 6th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $3.67.

Mersana Therapeutics Trading Down 4.8 %

Shares of Mersana Therapeutics stock opened at $0.32 on Thursday. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. The company’s fifty day moving average price is $0.38 and its two-hundred day moving average price is $1.07. Mersana Therapeutics has a 52-week low of $0.26 and a 52-week high of $2.88. The firm has a market capitalization of $39.74 million, a PE ratio of -0.52 and a beta of 1.32.

Mersana Therapeutics (NASDAQ:MRSN) last posted its earnings results on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The firm had revenue of $16.36 million for the quarter, compared to the consensus estimate of $7.71 million.

Institutional Trading of Mersana Therapeutics

Several large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. acquired a new stake in Mersana Therapeutics in the 4th quarter valued at about $37,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Mersana Therapeutics in the fourth quarter valued at approximately $65,000. Avanza Fonder AB bought a new position in Mersana Therapeutics in the 4th quarter worth approximately $81,000. Oxford Asset Management LLP acquired a new position in Mersana Therapeutics during the 4th quarter worth $94,000. Finally, Wells Fargo & Company MN boosted its position in Mersana Therapeutics by 40.3% in the 4th quarter. Wells Fargo & Company MN now owns 67,483 shares of the company’s stock valued at $97,000 after buying an additional 19,368 shares during the last quarter. Institutional investors own 93.92% of the company’s stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.